RESUMEN
BACKGROUND: Satellitosis or in-transit metastasis (S-ITM) has clinical outcomes comparable to node-positivity in cutaneous squamous cell carcinoma (cSCC). There is a need to stratify the risk groups. OBJECTIVE: To determine which prognostic factors of S-ITM confer an increased risk of relapse and cSCC-specific-death. METHODS: A retrospective, multicenter cohort study. Patients with cSCC developing S-ITM were included. Multivariate competing risk analysis evaluated which factors were associated with relapse and specific death. RESULTS: Of a total of 111 patients with cSCC and S-ITM, 86 patients were included for analysis. An S-ITM size of ≥20 mm, >5 S-ITM lesions, and a primary tumor deep invasion was associated with an increased cumulative incidence of relapse (subhazard ratio [SHR]: 2.89 [95% CI, 1.44-5.83; P = .003], 2.32 [95% CI, 1.13-4.77; P = .021], and 2.863 [95% CI, 1.25-6.55; P = .013]), respectively. Several >5 S-ITM lesions were also associated with an increased probability of specific death (SHR: 3.48 [95% CI, 1.18-10.2; P = .023]). LIMITATIONS: Retrospective study and heterogeneity of treatments. CONCLUSION: The size and the number of S-ITM lesions confer an increased risk of relapse and the number of S-ITM an increased risk of specific-death in patients with cSCC presenting with S-ITM. These results provide new prognostic information and can be considered in the staging guidelines.
Asunto(s)
Carcinoma de Células Escamosas , Neoplasias Cutáneas , Humanos , Carcinoma de Células Escamosas/patología , Estudios de Cohortes , Estudios Retrospectivos , Pronóstico , Neoplasias Cutáneas/patología , Recurrencia Local de Neoplasia/epidemiología , Recurrencia Local de Neoplasia/patología , Factores de Riesgo , Recurrencia , Estadificación de NeoplasiasRESUMEN
Antecedentes y objetivo: la evolución a largo plazo en pacientes con COVID-19 no es suficientemente conocida. El objetivo es estimar la prevalencia de la COVID persistente (estado post-COVID-19) a los 6 y 12 meses en una cohorte poblacional.Material y métodos: estudio observacional, ambispectivo, realizado en un centro de Atención Primaria, incluyendo pacientes de 18-65 años con COVID-19 diagnosticado entre julio y diciembre de 2020. Se hicieron entrevistas telefónicas a los 6 y 12 meses, analizando la persistencia de síntomas, estado de salud e inicio de psicofármacos.Resultados: de 143 pacientes, 116 completaron el seguimiento (edad media: 43,6 años, 59% hombres). El 95,7% tuvieron infección leve, siendo el síntoma más frecuente la fatiga (69,8%). El número de síntomas disminuyó tras 6 (p <0,001) y 12 meses (p <0,001), mejorando la percepción de salud (p <0,001) y disminuyendo el tratamiento con psicofármacos (p = 0,04). Tenían estado post-COVID-19 el 41,4% (intervalo de confianza [IC] 95% 32,8-50,5) y el 8,6% (IC 95% 5,0-17,9) a los 6 y 12 meses, respectivamente. Conclusiones: casi todos los pacientes recuperaron su estado de salud a los 12 meses, con una prevalencia de estado post-COVID-19 inferior a la descrita.(AU)
Background and objective: long-term course in COVID-19 patients is not sufficiently known. The aim is to estimate the prevalence of post-COVID-19 condition at six and 12 months in a population cohort.Material and methods: observational, ambispective study, performed in a primary care centre, including patients aged 18-65 years with COVID-19 diagnosed between July-December 2020. Telephone interviews were conducted at six and 12 months, analyzing the persistence of symptoms, state of health and commencing psychotropic drugs.Results: of 143 patients, 116 completed follow-ups (mean age 43.6 years, 59% male). A total of 95.7% had mild infection, the most common symptom being fatigue (69.8%). The number of symptoms decreased after six (P<0.001) and 12 months (P<0.001), which improved the perception of health (P<0.001) and reducing treatment with psychoactive drugs (P=0.04). A total of 41.4% (95% CI 32.8-50.5) and 8.6% (95% CI 5.0-17.9) had post-COVID-19 condition at six and 12 months, respectively.Conclusions: almost all the patients recovered their health status at 12 months, with a prevalence of post-COVID-19 condition lower than that reported.(AU)